Aridis Pharmaceuticals (ARDS) — Fundamentals Overview

Shares of Biotechnology company Aridis Pharmaceuticals jumped 18.66% today. With many investors piling into ARDS without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

  • Aridis Pharmaceuticals has moved -63.18% over the last year, and the S&P 500 logged a change of -9.54%

  • ARDS has an average analyst rating of buy and is -90.92% away from its mean target price of $6.0 per share

  • Its trailing earnings per share (EPS) is $-1.83

  • Aridis Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -0.3 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $-0.81 and its forward P/E ratio is -0.67

  • The company has a Price to Book (P/B) ratio of 5.4 in contrast to the S&P 500's average ratio of 2.95

  • Aridis Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16

  • Aridis Pharmaceuticals, Inc., an advanced-stage biopharmaceutical company, is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The company is headquartered in Los Gatos, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.